People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Other Technology, Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Halio, Inc. | — | Other Technology | Series D+ | $551.9M | $1.1B | 2013 |
| Cidara Therapeutics, Inc. | — | Biotechnology | Series D+ | $349.1M | $2.8B | 2014 |
| Rennovia Inc | — | Other Technology | Series B | $81.0M | $60.9M | 2009 |
| Expansion Therapeutics, Inc. | — | Pharmaceuticals | Series C | $78.3M | $1.1B | 2016 |
| Pulmatrix Inc | — | Biotechnology | Series B | $69.6M | $396.9M | 2015 |
| Pulmatrix, Inc. | — | Pharmaceuticals | Series B | $62.9M | $86.2M | 2015 |
| Novira Therapeutics, Inc. | — | Pharmaceuticals | Series B | $48.0M | $306.0M | 2012 |
| Variation Biotechnologies (US), Inc. | — | Biotechnology | Series A | $17.1M | $54.2M | 2010 |
| Albamunity, Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.8M | 2020 |
SCOTT ROCKLAGE at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SCOTT ROCKLAGE on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 3 | 23 |
| Kevin Forrest | 3 | 3 |
| Michael Higgins | 2 | 9 |
| Terrance McGuire | 2 | 9 |
| Robert Clarke | 2 | 7 |
| Kurt Graves | 2 | 5 |
| Scott M. Rocklage | 2 | 4 |
| David Hava | 2 | 2 |
| David Maki | 2 | 2 |
| Dipender Saluja | 1 | 16 |
| Steve Gillis | 1 | 13 |
| Patrick Heron | 1 | 11 |
| Nina Kjellson | 1 | 11 |
| Tim Shannon | 1 | 9 |
| Meredith Fisher | 1 | 6 |
| Jason Hafler | 1 | 6 |
| Paul Stone | 1 | 5 |
| Kevin Moore | 1 | 5 |
| Roger Kitterman | 1 | 5 |
| Amit Munshi | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.